PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
| Contacts: | |
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$10.73 |
| Daily Change: | 0.13 1.23 |
| Daily Volume: | 364,936 |
| Market Cap: | US$627.060M |
February 06, 2025 September 03, 2024 August 09, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
